3.92
-0.16 (-3.92%)
| Penutupan Terdahulu | 4.08 |
| Buka | 3.99 |
| Jumlah Dagangan | 245,286 |
| Purata Dagangan (3B) | 438,019 |
| Modal Pasaran | 221,222,064 |
| Harga / Buku (P/B) | 1.29 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
| EPS Cair (TTM) | -1.68 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.68% |
| Nisbah Semasa (MRQ) | 17.49 |
| Aliran Tunai Operasi (OCF TTM) | -81.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.58 M |
| Pulangan Atas Aset (ROA TTM) | -23.36% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.52% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Astria Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 2.50 |
|
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.47% |
| % Dimiliki oleh Institusi | 104.63% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 47.00 (Cantor Fitzgerald, 1,098.98%) | Beli |
| Median | 28.00 (614.29%) | |
| Rendah | 16.00 (HC Wainwright & Co., 308.16%) | Beli |
| Purata | 30.33 (673.72%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 5.86 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 14 May 2025 | 47.00 (1,098.98%) | Beli | 3.97 |
| 29 Apr 2025 | 47.00 (1,098.98%) | Beli | 5.12 | |
| Wedbush | 12 Mar 2025 | 28.00 (614.29%) | Beli | 7.14 |
| HC Wainwright & Co. | 11 Mar 2025 | 16.00 (308.16%) | Beli | 6.47 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |